Comparative Pharmacology
Head-to-head clinical analysis: DESMODA versus MINIRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMODA versus MINIRIN.
DESMODA vs MINIRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.
10 mg orally once daily
Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.
None Documented
None Documented
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Terminal elimination half-life: 2–3 hours (intravenous, subcutaneous); 3–5 hours (oral). Clinical context: Short half-life necessitates frequent dosing; duration of antidiuretic effect may outlast plasma levels due to receptor binding.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Renal (primarily as unchanged drug via glomerular filtration and tubular secretion; ~65% of an intravenous dose excreted unchanged in urine within 24 hours); fecal (~5–10% of an oral dose); minimal biliary elimination.
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog